Peptide Comparison
TB-500 vs Klow
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
TB-500 has stronger documented evidence (Anecdotal + Animal Studies) than Klow (Anecdotal) while both occupy the tissue-repair class. When clinical-evidence tier is the deciding factor, TB-500 is the safer pick. Klow may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| TB-500 | Klow | |
|---|---|---|
| Class | Thymosin β4 fragment; tissue repair | Four-component regenerative blend (Glow + KPV anti-inflammatory) |
| Drug class | Tissue Repair | Tissue Repair |
| Mechanism | Binds and sequesters G-actin; promotes actin polymerization; upregulates angiogenesis and cell migration | Composite formulation layering matrikine signalling, cytoprotection, actin regulation, and NF-kB suppression: GHK-Cu (copper-peptide matrikine activating ~4,000 wound-healing / collagen-elastin genes), BPC-157 (angiogenesis via VEGFR2 + epithelial / tendon repair), TB-500 (actin sequestration + stem-cell mobilisation + anti-fibrotic), KPV (alpha-MSH-derived tripeptide inhibiting NF-kB at mucosal epithelium). Klow is essentially the Glow blend plus KPV for an inflammation-suppression arm. |
| Route | SC / IM | SC injection |
| Half-life | Several hrs to days (tissue uptake) | Composite: hours to days per component (TB-500 longest) |
| Dosage (research) | 2-2.5 mg SC/IM 2x weekly for 4-6 week load; then 2 mg monthly | Typical SC protocols deliver ~250 mcg of each component daily (per-component basis from a combined-mg vial) for 4-8 week loading cycles. Confirm vial composition with vendor before computing per-component dose |
| Evidence tier | Anecdotal + Animal Studies | Anecdotal |
| Research depth | 32 indexed | — |
| Availability | Compounding Restricted | Compounding Restricted |
| Reported risks | WADA-banned; limited human data; injection site pain; lethargy; theoretical proliferation concerns | No human-trial data on the combined formulation; each component carries its own risk profile (TB-500 WADA-banned, theoretical pro-proliferative concerns; copper accumulation at chronic GHK-Cu doses); injection-site reactions; meaningful batch-to-batch composition variability across compounders |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick TB-500 or Klow?
TB-500 has stronger documented evidence (Anecdotal + Animal Studies) than Klow (Anecdotal) while both occupy the tissue-repair class. When clinical-evidence tier is the deciding factor, TB-500 is the safer pick. Klow may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between TB-500 and Klow?
TB-500 is classed as Thymosin β4 fragment; tissue repair; Klow is classed as Four-component regenerative blend (Glow + KPV anti-inflammatory). Reported mechanism: TB-500, Binds and sequesters G-actin; promotes actin polymerization; upregulates angiogenesis and cell migration; Klow, Composite formulation layering matrikine signalling, cytoprotection, actin regulation, and NF-kB suppression: GHK-Cu (copper-peptide matrikine activating ~4,000 wound-healing / collagen-elastin genes), BPC-157 (angiogenesis via VEGFR2 + epithelial / tendon repair), TB-500 (actin sequestration + stem-cell mobilisation + anti-fibrotic), KPV (alpha-MSH-derived tripeptide inhibiting NF-kB at mucosal epithelium). Klow is essentially the Glow blend plus KPV for an inflammation-suppression arm. Reported half-life: TB-500, Several hrs to days (tissue uptake); Klow, Composite: hours to days per component (TB-500 longest). Routes in published studies: TB-500, SC / IM; Klow, SC injection.
Which has stronger evidence, TB-500 or Klow?
TB-500 and Klow sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. TB-500 is graded Anecdotal + Animal Studies, with 3 cited sources on its reference page and 32 indexed studies. Klow is graded Anecdotal, with 4 cited sources on its reference page.
Which is more accessible, TB-500 or Klow?
Neither TB-500 nor Klow is an FDA-approved drug. Catalog status: TB-500, Compounding Restricted; Klow, Compounding Restricted. FDA's Pharmacy Compounding Advisory Committee voted 8 for, 6 against, 1 abstention on 23 July 2026 to recommend TB-500 for the 503A Bulks List; the vote is advisory and changes nothing by itself.
Are TB-500 and Klow ever combined?
TB-500 and Klow appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…